TSC Talks 3.0 Research~Episode 3

Taking a break from the harsh closed loops and hunkering down in dis stone chamber to give a little freestyle riff for this episode from the stone chamberno links except go watch the video. the audio just won't cut it on this onehttps://youtu.be/bEIqg2lcDU0Become a supporter of this podcast: https://www.spreaker.com/podcast/tsc-talks--1666046/support.

I bust through the third wall or whatevs in Episode 10 of TSC Talks 3.0 Research. Dropped the whiteboard til the end. Summed up the 9 episodes and added a bit on the end about CPTSD, TAND and the fact that the entire family system is drawn into the grid as data churnin' emotin' node. Used the Google AI to investigate the theories I had on amplification of TSC by multiple factors for purpose and product and it proved true based on the research plus lived experience thus far.Source Links for Further ResearchI. Rare Disease Advocacy and Funding (Conflicts of Interest)[TSC Alliance: Corporate Policies](https://www.tscalliance.org/about-tsc/corporate-policies/)[TSC Alliance: COVID-19 Vaccine Position Statement](https://www.tscalliance.org/wp-content/uploads/2021/08/TSC-Alliance-COVID-19-Vaccine-Position-Statement-Update-August-2021-FINAL.pdf)[TSC Alliance: Phenotypic Variability Research](https://www.tscalliance.org/tsc-matters/phenotypic-variability-in-tuberous-sclerosis-complex-tsc/)[TSC Alliance: 2024 Talking Points](https://www.tscalliance.org/wp-content/uploads/2024/01/2024-Talking-Points-Final.pdf)[NORD: Mission and Values](https://rarediseases.org/about-us/mission-values/)[NORD: Research Grant Programs](https://rarediseases.org/advancing-research/research-grant-programs/) [EURORDIS: Our Funding](https://www.eurordis.org/who-we-are/our-funding/)[Mass General: Herscot $50 Million Gift](https://giving.massgeneral.org/stories/herscots-make-50-million-gift-to-mass-general)[NEJM: Industry Support for Patient Advocacy](https://www.nejm.org/doi/full/10.1056/NEJMsr1610625)II. Gene Therapy (CRISPR), Risks, and Regulation [FDA: Cellular & Gene Therapy Products](https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products)[CRISPR-Cas9 Off-Target Effects (Synthego)](https://www.synthego.com/blog/crispr-off-target-editing/)[CRISPR: Genome Engineering Advantages and Limitations (Taconic)](https://www.taconic.com/resources/crispr-genome-engineering-advantages-limitations)[FDA: Regulatory Distinctions for Cell and Gene Therapies (LinkedIn)](https://www.linkedin.com/pulse/fda-vs-ema-key-regulatory-distinctions-cell-gene-therapies-ywzye) [Informed Consent and Clinical Trials (PMC)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2659702/) [Immune Evasion in Engineered CRISPR Enzymes (Broad Institute)](https://www.broadinstitute.org/news/scientists-engineer-crispr-enzymes-evade-immune-system) [The Ethics of Gene Editing (Innovative Genomics)](https://innovativegenomics.org/crisprpedia/crispr-ethics/)III. Vaccines, Toxins, and Environmental Amplification [TSC Drug Market & Prevalence (OpenPR)](https://www.openpr.com/news/3536609/tuberous-sclerosis-complex-drug-market-2034-epidemiology)[Vaccines and the Rise in Pediatric Cancer (The Vaccine Reaction)](https://thevaccinereaction.org/2018/05/is-there-a-link-between-vaccines-and-the-rise-in-pediatric-cancer/) [Study of Vaccinated and Unvaccinated Children (Weston A. Price)](https://www.westonaprice.org/health-topics/vaccinations/chronic-disease-a-study-of-vaccinated-and-unvaccinated-children/#gsc.tab=0)[Role of Environmental Toxins in Epigenetic Dysregulation (PLM Institute)](https://plminstitute.org/plmi-blog/the-role-of-environmental-toxins-in-epigenetic-dysregulation/) [Childhood Vaccination Schedule Explosion (Twitter - NVICLoeDown)](https://twitter.com/NVICLoeDown/status/1687176816774033408) [COVID-19 Vaccine Added to Childhood Schedule (Children's Health Defense)](https://childrenshealthdefense.org/defender/childhood-covid-vaccine-schedule/) [The Role of Environmental Exposures in Genetic Disease (PMC)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4021822/)IV. Alternative and Holistic Approaches[Ketogenic Diet Inhibits the mTOR Pathway (AESnet)](https://aesnet.org/abstractslisting/the-ketogenic-diet-inhibits-the-mammalian-target-of-rapamycin-\(mtor\)-pathway)[Ketogenic Diet for Epilepsy in TSC (PMC)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5540690/) [Curcumin Inhibits mTOR Activity (ScienceDirect)](https://www.sciencedirect.com/science/article/abs/pii/S0944711318304860)[Natural Treatment for TSC (Inspire Forum)](https://www.inspire.com/groups/tuberous-sclerosis-complex/discussion/natural-treatment-for-tsc/)[Natural Products and Patenting (PMC)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8521639/) [Anti-Inflammatory Living (Holistic Health Code)](https://www.holistichealthcode.com/articles/unlocking-metabolic-health)contact Jill: [email protected] a supporter of this podcast: https://www.spreaker.com/podcast/tsc-talks--1666046/support.

In this episode, I get into mitigation strategies related to the increasing reliance on tech with the arrival of 6G particularly for those living with a chronic and or rare disease that is on multiple medications and dependent on the grid. What would be considered alternative or holistic therapies such as grounding, sound therapy, ketogenic diet and exercise have all been proven to help support the full field in finding homeostasis even with a condition such as TSC and can improve overall health and quality of life as a support beyond meds and other more drastic regimens. I also talk about the similarities between CPTSD and TAND (TSC Associated Neuropsychiatric Disorder) and the importance of understanding the "energetics" of a rare disease when advocating for one's self and/or loved ones. The system will add additional labels and complicate understanding. I hope to explore further the CPTSD connection as I feel it as AS relevant as the limited focus of TAND.Full list of links: https://docs.google.com/document/d/e/2PACX-1vQv_yBMqtFvxQmhm31TXozv20_nEGxCTwjUCclYrEK2yE9NGR6rQqc1GyMsA76lUNtNrZda-FF_Z2IM/pubBecome a supporter of this podcast: https://www.spreaker.com/podcast/tsc-talks--1666046/support.

Episode 8 of TSC Talks 3.0 Research... continuing on with the extensive history of the rare disease Tuberous Sclerosis Complex, the set up for data harvesting and gene editing and the inevitability of enhanced grid adhesion. Woohoo! Next episode I'm gonna go into mitigation and the upswing of the sitch. Links:mindandbodyexercises.comhttps://medium.comhttps://maescenter.comrockarch.orgtikvahhealthandwellness.comnih.govnih.govnutritiondiagnostics.com.aunih.govpsychologytoday.comnih.govmcgill.cachop.eduhttps://historyofvaccines.orgnih.govjpeds.comhttps://time.comnih.govnih.govnih.gov2minutemedicine.comnih.govnih.govsciencedirect.comnih.govcdc.govnih.govhttps://richd.orgnih.govwikipedia.orgempr.comhttps://historyofvaccines.orghttps://drgreenmom.commayoclinic.orgkaiserpermanente.orgnih.govkff.orgforbes.comitu.intciocoverage.comhttps://studyfinds.orgBecome a supporter of this podcast: https://www.spreaker.com/podcast/tsc-talks--1666046/support.

The history of Tuberous Sclerosis Complex.they're juicing it.Some queries related to the complexity of epigenetic variables and the overlords decision to focus on genetics only for the sake of "simplicity"...Just my opinion?I welcome all listeners and critical thinkers.📚 Primary Research & Databases PubMed Central (Full-Text Archive): https://pmc.ncbi.nlm.nih.govPubMed (Citations & Abstracts): https://pubmed.ncbi.nlm.nih.govScienceDirect: sciencedirect.comWiley Online Library: https://onlinelibrary.wiley.comSpringer Link: https://link.springer.comResearchGate: researchgate.net Academia.edu: academia.edu🏥 Health Organizations & Agencies NIH / National Library of Medicine: https://www.ncbi.nlm.nih.govNINDS (Neurological Disorders): https://www.ninds.nih.govMedlinePlus: https://medlineplus.govHRSA (Health Resources): hrsa.govTexas Children’s Hospital: texaschildrens.orgTSC Alliance: tscalliance.orgEpilepsy Foundation: epilepsy.com🔬 Specialized Medical JournalsThe Lancet: thelancet.com Pediatric Neurology: pedneur.comNeurotherapeutics: neurotherapeuticsjournal.orgFrontiers in Science: frontiersin.org eLife Sciences: https://elifesciences.orgAMA Journal of Ethics: ama-assn.orgAAP Publications: aap.org ACR Journals: https://acrjournals.onlinelibrary.wiley.comACR Abstracts: https://acrabstracts.org2 Minute Medicine: https://www.2minutemedicine.com📰 News, Legal & Historical ContextTIME Magazine: https://time.comMedical Xpress: https://medicalxpress.comHistory of Vaccines: https://historyofvaccines.orgTexas Vaccine Lawyers: texasvaccinelawyers.comDigital Commons (Rockefeller): rockefeller.edu HealthCentral: healthcentral.com Changing Aging: https://changingaging.orgMedium: https://medium.comMeridian Health Clinic: https://meridianhealthclinic.comWikipedia: wikipedia.org WikiDoc: wikidoc.orgcontact Jill ~ [email protected] a supporter of this podcast: https://www.spreaker.com/podcast/tsc-talks--1666046/support.

In Episode 6 of TSC Talks Research 3.0, I finish up the discussion of CRISPR and TSC and the trajectory, I get into cannabis and the way they've deglimmered exploration of consciousness for those with rare diseases on hefty meds and how this relates to the cultivated biosphere that limits the full potential of the divine human. So many the templates for data and experimentation to build the current Healthcare 4.0 system and Precision Medicine. While many will be helped, there will be a dependence on the grid system.YouTube Video: https://youtu.be/OqLKIZ7Q54s?si=8svWmKHp4ekiFOnRLinks: https://www.liebertpub.com/doi/10.1089/crispr.2024.0079 https://pubmed.ncbi.nlm.nih.gov/39654514/ https://pediatricsnationwide.org/2024/01/11/innovative-gene-therapy-approach-for-treating-patients-with-tuberous-sclerosis-type-2/ https://pmc.ncbi.nlm.nih.gov/articles/PMC7793581/ https://innovativegenomics.org/news/crispr-clinical-trials-2026/ https://frontlinegenomics.com/sickle-cell-disease-a-2024-update/ epidiolexhcp.com nih.gov sciencedaily.com https://www.researchgate.net/publication/348347376_Gene_therapy_for_tuberous_sclerosis_complex_type_2_in_a_mouse_model_by_delivery_of_AAV9_encoding_a_condensed_form_of_tuberin globalgenes.org neurologylive.com berkeley.edu ccf.orgBecome a supporter of this podcast: https://www.spreaker.com/podcast/tsc-talks--1666046/support.

In this episode I share information on the risks and side effects of CRISPR for individuals with TSC and in general as well as go into how those affected with TSC are "test bunnies" for much of this new technology, and my theories with documentation of why this is happening. I also go over some of the "no touch" technologies being rolled out and tested on those with diseases such as TSC where the nature of the genetics, a "monogenic" disorder, makes it a more suitable population to experiment on to gain information than other more common disorders, such as Alzheimer's, which involve 100s of genetic factors.  TSC population is kept in that "test bunny" role without ever addressing the external factors that make the disease more difficult to manage in the first place.LINKS:pmc.ncbi.nlm.nih.govpubmed.ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC7672342/https://cdmrp.health.mil/tscrp/defaulthttp://tuberous-sclerosis.org/research/tsa-funded-research/https://www.mdpi.com/2075-1729/15/3/368https://www.tscalliance.org/wp-content/uploads/2023/02/Training-Packet-Documents.pdfhttps://pmc.ncbi.nlm.nih.gov/articles/PMC3010088/https://pmc.ncbi.nlm.nih.gov/articles/PMC4527140/https://pubmed.ncbi.nlm.nih.gov/19028034/https://pmc.ncbi.nlm.nih.gov/articles/PMC6851053/https://www.youtube.com/watch?v=hXRRq-dFuYghttps://www.youtube.com/watch?v=Hu2TvhhdEHYhttps://www.youtube.com/watch?v=BFuXttZspaYhttps://pmc.ncbi.nlm.nih.gov/articles/PMC5727703/https://globalgenes.org/raredaily/transforming-tsc-epilepsy-with-a-precision-therapy/https://pediatricsnationwide.org/2024/01/11/innovative-gene-therapy-approach-for-treating-patients-with-tuberous-sclerosis-type-2/https://pmc.ncbi.nlm.nih.gov/articles/PMC3164024/https://pmc.ncbi.nlm.nih.gov/articles/PMC11944049/https://www.biorxiv.org/content/10.1101/2024.02.22.581652v1.full-texthttps://pmc.ncbi.nlm.nih.gov/articles/PMC6408922/https://www.mdpi.com/2076-3417/14/3/1132https://pmc.ncbi.nlm.nih.gov/articles/PMC3744999/https://www.researchgate.net/publication/24217930_Magnetically_Responsive_Nanoparticles_for_Drug_Delivery_Applications_Using_Low_Magnetic_Field_Strengthshttps://pmc.ncbi.nlm.nih.gov/articles/PMC2933363/https://pmc.ncbi.nlm.nih.gov/articles/PMC7998448/https://pmc.ncbi.nlm.nih.gov/articles/PMC9230665/Become a supporter of this podcast: https://www.spreaker.com/podcast/tsc-talks--1666046/support.

TSC Talks 3.0 Research, Episode 4Here's my ongoing convo with AI delving into the funding behind rare disease research, non profits and how there are vested interests in continuing to bypass the full range of knowledge about what impacts the genome such as environmental (vaccines included) amplifications so they can justify the need for gene therapy via crispr, etchttps://rarediseases.org/about-us/financials-governance/https://rarediseases.org/collection/nord-financials/https://rarediseases.org/nord-releases-report-on-the-state-of-rare-disease-diagnosis-care-and-treatment-in-america-over-three-decades/https://rarediseases.org/nord-state-report-card/rarediseases.orghttps://rarediseases.org/wp-content/uploads/2022/10/NORD_2020_Annual-Report_wFinancials.pdfhttps://rarediseases.org/wp-content/uploads/2022/01/NORD_2020_Annual-Report_FINAL_SpreadView_web.pdfhttps://rarediseases.org/wp-content/uploads/2022/10/NRD-1198-2019_Annual-Report_FNL_WebSize.pdfhttps://www.eurordis.org/who-we-are/our-funding/https://www.eurordis.org/who-we-are/projects-and-partnerships/https://www.eurordis.org/partnerships/https://www.eurordis.org/get-involved/join-the-eurordis-round-table-of-companies/https://www.eurordis.org/publications/eurordis-policy-on-financial-support-by-commercial-companies-2/https://www.eurordis.org/our-priorities/research/https://www.eurordis.org/eurordis-supports-member-states-efforts-operating-grants-reintroduction/https://www.eurordis.org/videos/rare-but-real-talking-rare-diseases-part-1-6/download2.eurordis.orgvzacna-onemocneni.czhttps://everylifefoundation.org/rare-hub/rare-hub-partners-current-1-3/https://everylifefoundation.org/financial-support/https://everylifefoundation.org/everylifeeveryaction/https://everylifefoundation.org/sitemap/https://everylifefoundation.org/wp-content/uploads/2025/08/ELF-AnnualReport-2024-8.5x11-Proof-v6-081225.pdfhttps://everylifefoundation.org/wp-content/uploads/2022/01/Guide-to-Patient-Involvement-FINAL-COMPLETE-GUIDE-Rev.pdfhttps://everylifefoundation.org/wp-content/uploads/2016/05/Industry-Brochure-FINAL-May-2016.pdfBecome a supporter of this podcast: https://www.spreaker.com/podcast/tsc-talks--1666046/support.

Episode 3 of TSC Talks 3.0 ResearchI drill down with the AI on the reality of what is happening in the rare disease expanse. The full expanse it's not explored we are jumping right into gene editing, like using whiteout, it isn't quite the same. It's a closed loop system. That is for sure. links:https://www.ninds.nih.gov/health-information/disorders/tuberous-sclerosis-complex#https://pmc.ncbi.nlm.nih.gov/articles/PMC7672342/https://www.ncbi.nlm.nih.gov/books/NBK1220/#https://patienteducation.asgct.org/understanding-cell-gene-therapy/ethical-issues-germline-gene-editing# https://pmc.ncbi.nlm.nih.gov/articles/PMC12103018/# https://pubmed.ncbi.nlm.nih.gov/6873497/#https://pmc.ncbi.nlm.nih.gov/articles/PMC6277505/# https://www.researchgate.net/publication/326455213_Incidence_of_tuberous_sclerosis_and_age_at_first_diagnosis_new_data_and_emerging_trends_from_a_national_prospective_surveillance_studyhttps://pmc.ncbi.nlm.nih.gov/articles/PMC11944049/# https://www.slu.edu/law/health/blog/2024/vence-bonham-dss.php#https://tuberoussclerosiscenter.wustl.edu/about-tsc/causes/# https://www.ncbi.nlm.nih.gov/books/NBK535878/# https://pmc.ncbi.nlm.nih.gov/articles/PMC5524257/#https://pmc.ncbi.nlm.nih.gov/articles/PMC5100696/#https://link.springer.com/article/10.1007/s11569-025-00479-8# https://www.ncbi.nlm.nih.gov/books/NBK535877/# https://pmc.ncbi.nlm.nih.gov/articles/PMC11306935/# https://pmc.ncbi.nlm.nih.gov/articles/PMC10338708/https://www.thehastingscenter.org/genetic-therapies-for-rare-diseases-developing-ethical-regulatory-policies/# https://med.nyu.edu/departments-institutes/population-health/divisions-sections-centers/medical-ethics/education/high-school-bioethics-project/learning-scenarios/jesse-gelsinger-casehttps://www.cliffsnotes.com/cliffs-questions/5224266# https://www.bstquarterly.com/article/using-synthetic-biology-to-create-therapeutic-solutions/# https://www.sciencedirect.com/science/article/pii/S1359644621001574 https://www.sciencedirect.com/science/article/abs/pii/S1359644621001574##raredisease #TuberousSclerosisComplex #GeneEditingBecome a supporter of this podcast: https://www.spreaker.com/podcast/tsc-talks--1666046/support.

​Episode 2 of ongoing research on Tuberous Sclerosis Complex based on the query~Is CRISPR CAS9 being researched to help/cure tuberous sclerosis?"An exchange with Google AI mode in reference to the above query with the intention of making it clear the trajectory for those with rare diseases in terms of overriding our biological organic template and moving towards a more synthetic version. I picked up where I left off with Episode 1 and talk through Epigenetic "Switches", Gut-Brain Axis and Neuroinflammation, Why Researchers Are Skipping These Links, Potential Reasons for the Research Focus, Funding and Corporate Partnerships, Neuroinflammation Research, The "TAND" Project (TSC-Associated Neuropsychiatric Disorders), The PREVENT Trial, Basic Science and "Somatic Mosaicism", The "Funding Gap" regarding Conflicts of Interest, The Logic of the "Omission", Lived Experience vs. "Proven" Science,Why It Feels "Diabolical" & Finding the "Clean" Data https://www.mdpi.com/1422-0067/22/14/7273 https://pmc.ncbi.nlm.nih.gov/articles/PMC11275973/ https://www.ncbi.nlm.nih.gov/books/NBK206940/ https://www.nature.com/articles/s41398-024-02752-y https://clinicaltrials.gov/study/NCT01289912 https://pmc.ncbi.nlm.nih.gov/articles/PMC9253752/ https://www.intechopen.com/chapters/82669 https://pmc.ncbi.nlm.nih.gov/articles/PMC6748183/ https://pmc.ncbi.nlm.nih.gov/articles/PMC6278824/ https://www.nature.com/articles/s41439-022-00181-1 https://pmc.ncbi.nlm.nih.gov/articles/PMC3035853/ https://pmc.ncbi.nlm.nih.gov/articles/PMC5804531/ https://pubmed.ncbi.nlm.nih.gov/40558831/ https://docs.google.com/document/d/1ncDHvfDHkzVd1-H4Xgulz-mhSZxhwhydK6jWln90L5E/ (contact [email protected] for access)Become a supporter of this podcast: https://www.spreaker.com/podcast/tsc-talks--1666046/support.